RXRX RECURSION PHARMACEUTICALS, INC.companySEC Filings & Insider Trading Activity 2026
Latest RECURSION PHARMACEUTICALS, INC. (RXRX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for RECURSION PHARMACEUTICALS, INC. (RXRX) (SEC CIK 1601830), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: AI-native drug discovery platform integrating biology, chemistry, clinical development to accelerate novel medicine creation
- • New emphasis: Clinical validation of Recursion OS in 2025 with positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP)
Risk Factors
- • FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026
- • Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners
Management Discussion & Analysis
- • Revenue $74.7M in 2025, up 27% YoY from $58.8M driven by Sanofi partnership; 2024 revenue rose 32% from $44.6M primarily from Roche partnership
- • Operating margin negative 868% (loss $648.1M on revenue $74.7M) worsening from 815% in 2024 (loss $479.0M on $58.8M revenue)
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Recursion released an earnings presentation on Feb 25, 2026 in connection with its Q4/FY earnings call
- • Full presentation details in Exhibit 99.2 — key metrics and pipeline updates available there
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year fiscal 2025 earnings released February 25, 2026
- • Full results in Exhibit 99.1 — primary source for revenue, cash position, and pipeline spend details
Annual Reports Archive10-K
AI-powered analysis of RECURSION PHARMACEUTICALS, INC. (RXRX) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $39.8M | $44.6M | $58.8M | $74.7M |
| Operating Income | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| Net Income | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| Op. Margin | -616.7% | -785.3% | -814.1% | -867.9% |
| Net Margin | -601.0% | -736.0% | -788.0% | -863.4% |
| Balance Sheet | ||||
| Total Assets | $701.3M | $653.7M | $1.4B | $1.5B |
| Equity | $485.8M | $463.4M | $1.0B | $1.1B |
| ROE | -49.3% | -70.8% | -44.8% | -57.0% |
Source: XBRL financial data from RECURSION PHARMACEUTICALS, INC. (RXRX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Mar 25, 2026 | — | — | — |
8-K | Feb 25, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 8, 2025 | — | — | |
8-K | Nov 26, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 5, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Feb 27, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 23, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 13, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest RXRX SEC filings in 2026?
RECURSION PHARMACEUTICALS, INC. (RXRX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did RXRX file its most recent 10-K annual report?
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view RXRX 10-Q quarterly reports?
RECURSION PHARMACEUTICALS, INC. (RXRX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every RXRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has RXRX filed recently?
RECURSION PHARMACEUTICALS, INC. (RXRX)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RXRX insider trading activity (Form 4)?
SignalX aggregates every RXRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RXRX file with the SEC?
RECURSION PHARMACEUTICALS, INC. (RXRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RXRX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for RECURSION PHARMACEUTICALS, INC. (RXRX).
What is RXRX's SEC CIK number?
RECURSION PHARMACEUTICALS, INC. (RXRX)'s SEC CIK (Central Index Key) number is 1601830. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1601830 to look up all RXRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RXRX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from RECURSION PHARMACEUTICALS, INC. (RXRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of RECURSION PHARMACEUTICALS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 26+ filings.